Sutro Biopharma (STRO) 10-Q2023 Q1 Quarterly report

Filed: 15 May 23, 8:05am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: AACR, advisor, AGC, appeal, appointed, ballot, blockade, Capua, catastrophic, citizenship, clarify, CMO, composition, conception, correctly, CPPA, custodial, depository, downturn, dual, economy, ELAHERE, EMA, enrollee, exploratory, extraterritorially, FDIC, FDORA, fifteen, GmbH, hand, imperfect, incorrectly, inventor, IRC, letter, leverage, Likewise, luvelta, luveltamab, macroeconomic, movement, mutually, nonclinical, notify, pegfilgrastim, phenotype, preapproval, predominately, pseudonymized, RAM, receptor, registered, resurgence, revival, revived, Russian, solid, strong, tazevibulin, terminology, thereon, thereto, turmoil, tyrosine, underway, unfriendly, unintentionally, Unitary, UPC, weak, weigh, wider

Removed: accepting, add, adjusted, afflicted, amortized, array, assessed, assisting, asymptomatic, breadth, breast, Brexit, canceled, capable, CDC, CJEU, colony, commerce, consolidation, constitute, contact, converted, corrective, cybersecurity, deceptive, defended, desire, destination, discontinuation, disinfection, distancing, EEA, EGFR, emerge, escrow, evidenced, executed, exemption, experiencing, Facebook, fine, FTC, gave, German, GMP, granulocyte, home, incremental, indefinite, intention, Internationally, Irish, job, Jumpstart, jurisdictional, Justice, Kenilworth, keratopathy, lab, leasehold, leukemia, losing, lung, lymphoma, Macau, mechanism, merger, ministerial, missed, missing, modifying, network, NJ, NY, originating, OSHA, outbreak, oversee, participant, participating, passed, people, pharmacovigilance, postpone, precautionary, precursor, prepare, preventive, pronounced, quarantine, real, reallocation, reclassified, refundable, regime, Relatedly, relaxed, relying, Removal, renegotiation, Republic, responding, resume, resumption, retention, returned, sensitivity, serving, Shield, speed, spread, staffing, stimulating, stronger, substance, sudden, supervising, supervisory, supplementary, sustained, Switzerland, Taiwan, territory, transferred, transit, transitional, transmitting, turnover, ultimate, unfair, unfounded, unit, unsecured, upheld, variation, VCDPA, withdrawing, worsen, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

STRO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Edward C. Albini, Chief Financial Officer of Sutro Biopharma, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 15, 2023	/s/ Edward C. Albini
	Edward C. Albini
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)